What KRAS mutations, if any, would you omit when using daraxonrasib in patients with metastatic pancreatic adenocarcinoma?

There is no reason to exclude any RAS mutation or RAS wild-type tumors. All types demonstrated benefit in the RASolute 302 study, albeit in smaller numbers. All PDAC patients should be considered for daraxonrasib in the second-line setting, as it is superior to second-line chemo.

The phase I study may shed some light on this matter (O'Reilly et al., PMID 42223072). The non-G12 in this population, as mentioned in the footnote of Table 3, were: KRAS G13D (1 patient), KRAS Q61H (14 patients), KRAS Q61R (2 patients), and KRAS Q61K (2 patients). So fair to say that this study had...